Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Apple Turns 50: From Garage Startup to AI Crossroads 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
 - EconoTimes)
Uppsala, Sweden, December 21, 2016 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today presented positive results from a recently completed dose-finding study of weekly administration of Apealea (Paclical).
The study included 48 patients with metastatic breast cancer that were treated weekly with Apealea (Paclical) starting at 100 mg/m2 and increasing in steps of 10 mg/m2 until 250 mg/m2 was reached. The pre-defined, dose-limiting toxicity as defined in the study protocol was not reached until 250 mg/m2 per week. An overall analysis of all adverse events recorded in the study defined 180 mg/m2 as the level for dose-limiting toxicity. The suggested dose for further development of weekly administration of Apealea is 170 mg/m2.
29 patients continued in a follow-up study for an additional one (1) to 22 weekly cycle(s). Efficacy was assessed through computed tomography in 26 patients: one (1) had complete response, two (2) partial responses, and 23 stable disease. The remaining three (3) patients left the study due to progressive disease. The safety assessments of the follow-up study confirmed the dose of 170 mg/m2 as suitable for further development.
“We are pleased to present results indicating our dosing regime is becoming increasingly accurate and tolerable for patients,” said Margareta Eriksson, Vice President of Clinical Development at Oasmia Pharmaceutical. “This study within the indication of breast cancer, one that affects so many women worldwide, positions Apealea as having significant potential for both patients as well as the physicians who treat them.”
Notes to editors:
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
http://www.globenewswire.com/NewsRoom/AttachmentNg/b1e690fe-c304-440f-a5f7-1e66b78fc20d
Julian Aleksov, Executive Vice Chairman Phone: +46 18 50 54 40 E-mail: [email protected] For Media Inquiries: Eric Fischgrund [email protected]
